Tags

Type your tag names separated by a space and hit enter

Prokinetic agents: a key in the future of gastroenterology.
Gastroenterol Clin North Am 1989; 18(2):437-57GC

Abstract

Prokinetic drugs enhance the motility of the luminal organs of the gastrointestinal tract. Few drugs developed in this decade are likely to have a greater impact on the treatment of disorders of the gastrointestinal tract. Bethanechol and metaclopramide have proven the potential utility of this class of drugs, whereas newer agents promise to have both a greater margin of safety and tolerability and a broader scope of utility. The efficacy of these agents is reviewed for the treatment of impaired motility from gastroesophageal reflux to severe chronic constipation.

Authors+Show Affiliations

University of Pennsylvania School of Medicine, Philadelphia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

2668178

Citation

Reynolds, J C.. "Prokinetic Agents: a Key in the Future of Gastroenterology." Gastroenterology Clinics of North America, vol. 18, no. 2, 1989, pp. 437-57.
Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am. 1989;18(2):437-57.
Reynolds, J. C. (1989). Prokinetic agents: a key in the future of gastroenterology. Gastroenterology Clinics of North America, 18(2), pp. 437-57.
Reynolds JC. Prokinetic Agents: a Key in the Future of Gastroenterology. Gastroenterol Clin North Am. 1989;18(2):437-57. PubMed PMID: 2668178.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prokinetic agents: a key in the future of gastroenterology. A1 - Reynolds,J C, PY - 1989/6/1/pubmed PY - 1989/6/1/medline PY - 1989/6/1/entrez SP - 437 EP - 57 JF - Gastroenterology clinics of North America JO - Gastroenterol. Clin. North Am. VL - 18 IS - 2 N2 - Prokinetic drugs enhance the motility of the luminal organs of the gastrointestinal tract. Few drugs developed in this decade are likely to have a greater impact on the treatment of disorders of the gastrointestinal tract. Bethanechol and metaclopramide have proven the potential utility of this class of drugs, whereas newer agents promise to have both a greater margin of safety and tolerability and a broader scope of utility. The efficacy of these agents is reviewed for the treatment of impaired motility from gastroesophageal reflux to severe chronic constipation. SN - 0889-8553 UR - https://www.unboundmedicine.com/medline/citation/2668178/Prokinetic_agents:_a_key_in_the_future_of_gastroenterology_ L2 - https://www.lens.org/lens/search?q=citation_id:2668178 DB - PRIME DP - Unbound Medicine ER -